Press releaseBusiness Wire
Nevro LLC
NVRO · NYSE
Price unavailable right now.
No price history for this range.
Latest news
- Press releasePRNewswire
Nevro Reports Fourth-Quarter and Full-Year 2024 Financial Results
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AMPS, PLYA, NVRO on Behalf of Shareholders
- Press releasePRNewswire
Shareholder Alert: The Ademi Firm investigates whether Nevro Corp. is obtaining a Fair Price for its Public Shareholders
- Press releasePRNewswire
Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm
- Press releaseBusiness Wire
NEVRO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Nevro Corp. - NVRO
- Press releasePRNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVRO, SLRN, PLYA on Behalf of Shareholders
- Press releasePRNewswire
Kuehn Law Encourages NVRO, SLRN, TGI, and PTMN Investors to Contact Law Firm
- News
Demystifying Nevro: Insights From 11 Analyst Reviews
- Press releasePRNewswire
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Nevro Corp. - NVRO
- Press releaseBusiness Wire
NVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Nevro Corp. Is Fair to Shareholders
- Press releaseBusiness Wire
Shareholder Alert: Ademi & Fruchter LLP Investigates Whether Nevro Corp. Is Obtaining a Fair Price for Its Public Shareholders
- Press releaseGlobe Newswire
Globus Medical to Acquire Nevro Corp. to Expand Treatment Options for Patients
- Press releasePRNewswire
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- Press releasePRNewswire
Nevro Announces Preliminary Fourth-Quarter and Full-Year 2024 Revenue Results
- News
Where Nevro Stands With Analysts
- Press releasePRNewswire
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- NewsVandana Singh
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
- News
What Analysts Are Saying About Nevro Stock
- Press releasePRNewswire
New Study Demonstrates Multiple Advantages of Nevro1™, the Novel SI Joint Fusion System by Nevro, in Comparison to Posterolateral and Lateral Approaches
- Press releasePRNewswire
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Peeling Back The Layers: Exploring Nevro Through Analyst Insights
- Press releasePRNewswire
Nevro's HFX iQ™ Spinal Cord Stimulation with AI Technology Receives CE Mark Certification in Europe, Increasing Product Expansion Globally
- Press releasePRNewswire
Nevro Reports Third-Quarter 2024 Financial Results
- Press releasePRNewswire
Nevro Reports Third-Quarter 2024 Financial Results
- News
Earnings Scheduled For November 11, 2024
- News
A Look Ahead: Nevro's Earnings Forecast
- Press releasePRNewswire
New Data Demonstrates Long-Term Improvements in Pain Intensity with Nevro's High-Frequency Spinal Cord Stimulation Therapy
- Press releasePRNewswire
Nevro Announces New Employee Inducement Grants Under NYSE Rule 303A.08
- Press releasePRNewswire
Nevro to Report Third-Quarter 2024 Financial Results and Host Earnings Conference Call on November 11, 2024
- News
Breaking Down Nevro: 10 Analysts Share Their Views
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.